Compare JPMorgan Chase & Co (JPM) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JPMorgan Chase & Co vs State Street SPDR S&P Biotech ETF — how do they compare? JPMorgan Chase & Co trades at $342.28 (market cap $900.78B), while State Street SPDR S&P Biotech ETF trades at $153.19. The key difference: JPMorgan Chase & Co pays a 1.77% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals.
| JPM | XBI | |
|---|---|---|
Market Cap | $900.78B | — |
Volume | 10,479,943 | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $346.91 | $164.28 |
52-Week Low | $282.84 | $85.16 |
Dividend Yield | 1.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JPMorgan Chase & Co. (JPM) trades at $342.57, up 0.43% on the day, with a bullish technical outlook supported by moving averages. The stock shows strong fundamentals with a P/E of 14.52 and net income margin of 33.4%, though Q4 2025 EPS missed expectations. Recent news highlights CEO Jamie Dimon's economic warnings and upcoming Q1 2026 earnings, with analyst consensus leaning bullish.
JPM offers upside to the $372.73 consensus price target, driven by earnings beats and sector resilience, but faces risks from geopolitical tensions, cybersecurity threats, and volatile cash flows. Investors should weigh solid profitability against macroeconomic headwinds highlighted in recent shareholder communications.
XBI, the SPDR S&P Biotech ETF, trades at $150.94, down 2.14% today amid a bearish technical signal. The ETF holds 155 biotech stocks equally weighted, offering high beta exposure. Recent news highlights a 17% monthly surge driven by AI drug discovery and M&A activity, though analyst consensus remains a lone Hold rating. Key support sits at $151 with resistance at $155.
Outlook hinges on biotech sector momentum from innovation and deal flow, but risks include volatility from small-cap holdings and regulatory uncertainty. The neutral sentiment and lack of fundamental ratios suggest investors await clearer earnings trends from underlying holdings for sustained gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About JPMorgan Chase & Co
JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.
Read more on JPM →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
